These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 31257237)

  • 21. Panels of HIV-1 Subtype C Env Reference Strains for Standardized Neutralization Assessments.
    Hraber P; Rademeyer C; Williamson C; Seaman MS; Gottardo R; Tang H; Greene K; Gao H; LaBranche C; Mascola JR; Morris L; Montefiori DC; Korber B
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28747500
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of Broadly Neutralizing Antibodies and Their Mapping by Monomeric gp120 in Human Immunodeficiency Virus Type 1-Infected Humans and Simian-Human Immunodeficiency Virus SHIVSF162P3N-Infected Macaques.
    Jia M; Lu H; Markowitz M; Cheng-Mayer C; Wu X
    J Virol; 2016 Apr; 90(8):4017-4031. PubMed ID: 26842476
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diversification in the HIV-1 Envelope Hyper-variable Domains V2, V4, and V5 and Higher Probability of Transmitted/Founder Envelope Glycosylation Favor the Development of Heterologous Neutralization Breadth.
    Smith SA; Burton SL; Kilembe W; Lakhi S; Karita E; Price M; Allen S; Hunter E; Derdeyn CA
    PLoS Pathog; 2016 Nov; 12(11):e1005989. PubMed ID: 27851829
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of susceptibility of HIV-1 CRF01_AE variants to neutralization by a panel of broadly neutralizing antibodies.
    Wang H; Yuan T; Li T; Li Y; Qian F; Zhu C; Liang S; Hoffmann D; Dittmer U; Sun B; Yang R
    Arch Virol; 2018 Dec; 163(12):3303-3315. PubMed ID: 30196320
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Achieving Potent Autologous Neutralizing Antibody Responses against Tier 2 HIV-1 Viruses by Strategic Selection of Envelope Immunogens.
    Hessell AJ; Malherbe DC; Pissani F; McBurney S; Krebs SJ; Gomes M; Pandey S; Sutton WF; Burwitz BJ; Gray M; Robins H; Park BS; Sacha JB; LaBranche CC; Fuller DH; Montefiori DC; Stamatatos L; Sather DN; Haigwood NL
    J Immunol; 2016 Apr; 196(7):3064-78. PubMed ID: 26944928
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunogenicity of a Prefusion HIV-1 Envelope Trimer in Complex with a Quaternary-Structure-Specific Antibody.
    Cheng C; Pancera M; Bossert A; Schmidt SD; Chen RE; Chen X; Druz A; Narpala S; Doria-Rose NA; McDermott AB; Kwong PD; Mascola JR
    J Virol; 2015 Dec; 90(6):2740-55. PubMed ID: 26719262
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Envelope characteristics in individuals who developed neutralizing antibodies targeting different epitopes in HIV-1 subtype C infection.
    Ndlovu B; Gounder K; Muema D; Raju N; Hermanus T; Mthethwa Q; Robertson K; Walker BD; Georgiev IS; Morris L; Moore PL; Ndung'u T
    Virology; 2020 Jul; 546():1-12. PubMed ID: 32275203
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emergence of broadly neutralizing antibodies and viral coevolution in two subjects during the early stages of infection with human immunodeficiency virus type 1.
    Sather DN; Carbonetti S; Malherbe DC; Pissani F; Stuart AB; Hessell AJ; Gray MD; Mikell I; Kalams SA; Haigwood NL; Stamatatos L
    J Virol; 2014 Nov; 88(22):12968-81. PubMed ID: 25122781
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HIV-1 Subtype C-Infected Children with Exceptional Neutralization Breadth Exhibit Polyclonal Responses Targeting Known Epitopes.
    Ditse Z; Muenchhoff M; Adland E; Jooste P; Goulder P; Moore PL; Morris L
    J Virol; 2018 Sep; 92(17):. PubMed ID: 29950423
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vaccine Induction of Heterologous Tier 2 HIV-1 Neutralizing Antibodies in Animal Models.
    Saunders KO; Verkoczy LK; Jiang C; Zhang J; Parks R; Chen H; Housman M; Bouton-Verville H; Shen X; Trama AM; Scearce R; Sutherland L; Santra S; Newman A; Eaton A; Xu K; Georgiev IS; Joyce MG; Tomaras GD; Bonsignori M; Reed SG; Salazar A; Mascola JR; Moody MA; Cain DW; Centlivre M; Zurawski S; Zurawski G; Erickson HP; Kwong PD; Alam SM; Levy Y; Montefiori DC; Haynes BF
    Cell Rep; 2017 Dec; 21(13):3681-3690. PubMed ID: 29281818
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cross-Neutralizing Antibodies in HIV-1 Individuals Infected by Subtypes B, F1, C or the B/Bbr Variant in Relation to the Genetics and Biochemical Characteristics of the env Gene.
    de Almeida DV; Macieira KV; Grinsztejn BG; Veloso Dos Santos VG; Guimarães ML
    PLoS One; 2016; 11(12):e0167690. PubMed ID: 27936047
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller.
    Freund NT; Wang H; Scharf L; Nogueira L; Horwitz JA; Bar-On Y; Golijanin J; Sievers SA; Sok D; Cai H; Cesar Lorenzi JC; Halper-Stromberg A; Toth I; Piechocka-Trocha A; Gristick HB; van Gils MJ; Sanders RW; Wang LX; Seaman MS; Burton DR; Gazumyan A; Walker BD; West AP; Bjorkman PJ; Nussenzweig MC
    Sci Transl Med; 2017 Jan; 9(373):. PubMed ID: 28100831
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Requirements for the Induction of Broadly Neutralizing Antibodies against HIV-1 by Vaccination].
    Vzorov AN; Uryvaev LV
    Mol Biol (Mosk); 2017; 51(6):945-957. PubMed ID: 29271959
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evolution of human immunodeficiency virus type 1 in a patient with cross-reactive neutralizing activity in serum.
    van Gils MJ; Edo-Matas D; Bowles EJ; Burger JA; Stewart-Jones GB; Schuitemaker H
    J Virol; 2011 Aug; 85(16):8443-8. PubMed ID: 21653664
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Detection of Broadly Neutralizing Activity within the First Months of HIV-1 Infection.
    Sanchez-Merino V; Fabra-Garcia A; Gonzalez N; Nicolas D; Merino-Mansilla A; Manzardo C; Ambrosioni J; Schultz A; Meyerhans A; Mascola JR; Gatell JM; Alcami J; Miro JM; Yuste E
    J Virol; 2016 Jun; 90(11):5231-5245. PubMed ID: 26984721
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HIV type 1 subtype A envelope genetic evolution in a slow progressing individual with consistent broadly neutralizing antibodies.
    Dieltjens T; Loots N; Vereecken K; Grupping K; Heyndrickx L; Bottieau E; Vanham G; Davis D; Janssens W
    AIDS Res Hum Retroviruses; 2009 Nov; 25(11):1165-9. PubMed ID: 19886837
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Env-2dCD4 S60C complexes act as super immunogens and elicit potent, broadly neutralizing antibodies against clinically relevant human immunodeficiency virus type 1 (HIV-1).
    Killick MA; Grant ML; Cerutti NM; Capovilla A; Papathanasopoulos MA
    Vaccine; 2015 Nov; 33(46):6298-306. PubMed ID: 26432912
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A broad range of mutations in HIV-1 neutralizing human monoclonal antibodies specific for V2, V3, and the CD4 binding site.
    Li L; Wang XH; Williams C; Volsky B; Steczko O; Seaman MS; Luthra K; Nyambi P; Nadas A; Giudicelli V; Lefranc MP; Zolla-Pazner S; Gorny MK
    Mol Immunol; 2015 Aug; 66(2):364-74. PubMed ID: 25965315
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neutralization breadth and potency of serum derived from recently human immunodeficiency virus type 1-infected Thai individuals.
    Chaitaveep N; Utachee P; Chuenchitra T; Karasavvan N; Takeda N; Kameoka M
    Microbes Infect; 2016 May; 18(5):346-53. PubMed ID: 26774333
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HIV-1 clade C escapes broadly neutralizing autologous antibodies with N332 glycan specificity by distinct mechanisms.
    Deshpande S; Patil S; Kumar R; Hermanus T; Murugavel KG; Srikrishnan AK; Solomon S; Morris L; Bhattacharya J
    Retrovirology; 2016 Aug; 13(1):60. PubMed ID: 27576440
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.